Bristol Myers Squibb gets FDA priority review for Breyanzi sBLA

Bristol Myers Squibb (BMS) has secured priority review from the US Food and Drug Administration (FDA) for its supplemental biologics license application (sBLA) for Breyanzi ... Read More